featured
Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma: 4-Year Overall Survival Update
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Ann. Oncol 2024 Feb 19;[EPub Ahead of Print], B Sangro, SL Chan, RK Kelley, G Lau, M Kudo, W Sukeepaisarnjaroen, M Yarchoan, EN De Toni, J Furuse, YK Kang, PR Galle, L Rimassa, A Heurgué, VC Tam, T Van Dao, SC Thungappa, V Breder, Y Ostapenko, M Reig, M Makowsky, MJ Paskow, C Gupta, JF Kurland, A Negro, GK Abou-AlfaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.